About 30% of AML patients with normal karyotype present with an activating FLT3 receptor mutation, most often as FLT3-ITD, and is the major intercessory of PI3K/Akt/mTOR pathway dysregulation. Here, AKT1 is linked to acute myeloid leukemia.